Valneva is a fully integrated vaccine company that specializes in the development, manufacture and commercialization of innovative vaccines with a mission to protect people from infectious diseases through preventative medicine. The Company seeks financial returns through focused R&D investments in promising product candidates and growing financial contributions from commercial products, striving towards financial self-sustainability. Valneva’s portfolio includes two commercial vaccines for travelers: one for the prevention of Japanese encephalitis (IXIARO®) and the second (DUKORAL®) indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. The Company has proprietary vaccines in development including candidates against Clostridium difficile and Lyme borreliosis. A variety of partnerships with leading pharmaceutical companies complement the Company’s value proposition and include vaccines being developed using Valneva’s innovative and validated technology platforms (EB66® vaccine production cell line, IC31® adjuvant). Valneva is incorporated in Lyon, France, listed on Euronext-Paris and the Vienna stock exchange and has operations in France, Austria, Scotland and Sweden with approximately 400 employees.
Show more
Type
Public
HQ
Lyon, FR
Size (employees)
17,686 (est)
Valneva is headquartered in Lyon, FR
Report incorrect company information

Key People/Management at Valneva

Thomas Lingelbach

Thomas Lingelbach

President & Chief Executive Officer

Valneva Office Locations

Valneva has an office in Lyon
Lyon, FR (HQ)
70, rue Saint Jean de Dieu
Show all (1)
Report incorrect company information

Valneva Financials and Metrics

Valneva Financials

Market capitalization (31-Oct-2017)

2.1 b

Closing share price (31-Oct-2017)

4.6
Valneva's current market capitalization is €2.1 b.
Show all financial metrics
Report incorrect company information